Rasagiline preclinical studies: implications for neuroprotection.
- Published in:
- 2006
- By:
- Publication type:
- Journal Article
Works matching IS 1082801X AND DT 2006 AND VI 41 AND IP 8
Results: 32
1
2
Efficacy and safety of rasagiline in the treatment of Parkinson disease.
- Published in:
- 2006
- By:
- Publication type:
- Journal Article
3
Pharmacology and pharmacokinetics of rasagiline: a selective, irreversible, second-generation MAO-B inhibitor.
- Published in:
- 2006
- By:
- Publication type:
- Journal Article
4
Pharmacologic management of Parkinson disease: treatment of levodopa-associated 'wearing off'.
- Published in:
- 2006
- By:
- Publication type:
- Journal Article
5
Pharmacologic management of Parkinson disease: initial therapy.
- Published in:
- 2006
- By:
- Publication type:
- Journal Article
6
Treatment strategies for Parkinson disease: role of rasagiline self-assessment quiz.
- Published in:
- 2006
- Publication type:
- Journal Article
7
Economic and quality-of-life implications of Parkinson disease and its treatment.
- Published in:
- 2006
- By:
- Publication type:
- Journal Article
8
Introduction.
- Published in:
- 2006
- By:
- Publication type:
- Journal Article
9
Challenges and considerations: a comparison of antidepressant classes in the development of pharmacoeconomic models.
- Published in:
- 2006
- By:
- Publication type:
- Journal Article
10
Policy watch: federal and state government actions and their impact on drug decision-makers. FDA announces advisory committee reform, supports adaptive trial designs; HHS report criticizes FDA postmarketing study policies.
- Published in:
- 2006
- By:
- Publication type:
- Journal Article
11
News capsules: what's new in drug research and managed care pharmacy. DPP-IV inhibitors effectively reduce levels of HbA1c as monotherapy or in combination with other agents.
- Published in:
- 2006
- By:
- Publication type:
- Journal Article
12
The role of pharmacoeconomics in formulary decision-making. Considerations for hospital and managed care pharmacy and therapeutics committees.
- Published in:
- 2006
- By:
- Publication type:
- Journal Article
13
Medication safety and reliability: a collection of the latest drug and news, notices, labeling changes, and drug availability issues. COX-2 inhibitor demonstrates lower incidence of adverse cardiorenal events compared with nonselective NSAIDs.
- Published in:
- 2006
- Publication type:
- Journal Article
14
Drug watch. Generalized anxiety disorder and sleep disorders.
- Published in:
- 2006
- By:
- Publication type:
- Journal Article
15
Drug and formulary trends.
- Published in:
- 2006
- Publication type:
- Journal Article
16
Selected websites.
- Published in:
- Formulary, 2006, v. 41, n. 8, p. 412
- Publication type:
- Article
17
Selected literature.
- Published in:
- Formulary, 2006, v. 41, n. 8, p. 412
- Publication type:
- Article
18
Generalized anxiety disorder and sleep disorders.
- Published in:
- Formulary, 2006, v. 41, n. 8, p. 412
- Publication type:
- Article
19
Drug and Formulary Trends.
- Published in:
- Formulary, 2006, v. 41, n. 8, p. 411
- Publication type:
- Article
20
FDA announces advisory committee reform, supports adaptive trial designs; HHS report criticizes FDA postmarketing study policies.
- Published in:
- Formulary, 2006, v. 41, n. 8, p. 406
- By:
- Publication type:
- Article
21
DPP-IV inhibitors effectively reduce levels of HbA<sub>1c</sub> as monotherapy or in combination with other agents.
- Published in:
- Formulary, 2006, v. 41, n. 8, p. 404
- By:
- Publication type:
- Article
22
Anidulafungin.
- Published in:
- Formulary, 2006, v. 41, n. 8, p. 387
- By:
- Publication type:
- Article
23
The role of pharmacoeconomics in formulary decision-making.
- Published in:
- Formulary, 2006, v. 41, n. 8, p. 374
- By:
- Publication type:
- Article
24
Safety: labeling updates & new warnings.
- Published in:
- Formulary, 2006, v. 41, n. 8, p. 372
- Publication type:
- Article
25
COX-2 inhibitor demonstrates lower incidence of adverse cardiorenal events compared with nonselective NSAIDs.
- Published in:
- Formulary, 2006, v. 41, n. 8, p. 372
- Publication type:
- Article
26
High-does non-COX-2 NSAIDs associated with increased vascular risk.
- Published in:
- Formulary, 2006, v. 41, n. 8, p. 371
- Publication type:
- Article
27
COX-2 inhibitors, nonselective NSAID use increases risk of death, reinfarction in acute MI patents.
- Published in:
- Formulary, 2006, v. 41, n. 8, p. 368
- Publication type:
- Article
28
FDA actions in brief.
- Published in:
- Formulary, 2006, v. 41, n. 8, p. 366
- Publication type:
- Article
29
New formulations.
- Published in:
- Formulary, 2006, v. 41, n. 8, p. 365
- Publication type:
- Article
30
First-time generic approvals.
- Published in:
- Formulary, 2006, v. 41, n. 8, p. 364
- Publication type:
- Article
31
New molecular entities/biologics.
- Published in:
- Formulary, 2006, v. 41, n. 8, p. 362
- Publication type:
- Article
32
Pipeline preview.
- Published in:
- Formulary, 2006, v. 41, n. 8, p. 362
- Publication type:
- Article